Vemurafenib

Vemurafenib Reactions 1680, p331 - 2 Dec 2017 Acantholytic dyskeratotic acanthoma: case report A 62-year-old woman developed acantholytic dyskeratotic acanthoma (ADA) following the therapy with vemurafenib. The woman was diagnosed with melanoma when she was 59 years old. She had undergone surgery, followed by nivolumab therapy. However, the disease progressed and advanced to systemic metastasis. Hence, to treat the multiple metastasis, she started receiving therapy with vemurafenib 960 mg/day [route not stated]. After one month of vemurafenib initiation, she developed a keratotic papule on her right shoulder. A skin biopsy of the papule was performed, which ruled out the possibility of squamous cell carcinoma. Histologically, the lesion demonstrated mild papillomatous acanthosis and hyperkeratosis. Acantholysis and dyskeratosis with corp ronds and grains were noted. Therefore, the papule was diagnosed as ADA that developed due to the vemurafenib therapy [outcome not stated]. Author comment: "In conclusion, we experienced a case of vemurafenib-induced ADA." Komori T, et al. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment. Journal of the European Academy of Dermatology and Venereology 31: e474-e475, No. 10, Oct 2017. Available from: URL: http:// doi.org/10.1111/jdv.14289 - Japan 803284154 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Vemurafenib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/vemurafenib-x69c7XkGNT
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39262-1
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p331 - 2 Dec 2017 Acantholytic dyskeratotic acanthoma: case report A 62-year-old woman developed acantholytic dyskeratotic acanthoma (ADA) following the therapy with vemurafenib. The woman was diagnosed with melanoma when she was 59 years old. She had undergone surgery, followed by nivolumab therapy. However, the disease progressed and advanced to systemic metastasis. Hence, to treat the multiple metastasis, she started receiving therapy with vemurafenib 960 mg/day [route not stated]. After one month of vemurafenib initiation, she developed a keratotic papule on her right shoulder. A skin biopsy of the papule was performed, which ruled out the possibility of squamous cell carcinoma. Histologically, the lesion demonstrated mild papillomatous acanthosis and hyperkeratosis. Acantholysis and dyskeratosis with corp ronds and grains were noted. Therefore, the papule was diagnosed as ADA that developed due to the vemurafenib therapy [outcome not stated]. Author comment: "In conclusion, we experienced a case of vemurafenib-induced ADA." Komori T, et al. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment. Journal of the European Academy of Dermatology and Venereology 31: e474-e475, No. 10, Oct 2017. Available from: URL: http:// doi.org/10.1111/jdv.14289 - Japan 803284154 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off